Brokerages Set Prothena Co. PLC (PRTA) Price Target at $37.33

Shares of Prothena Co. PLC (NASDAQ:PRTA) have received an average rating of “Hold” from the twelve research firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $33.86.

Several brokerages have issued reports on PRTA. BidaskClub upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research note on Wednesday. Oppenheimer reiterated a “hold” rating on shares of Prothena in a research note on Sunday, November 11th. ValuEngine upgraded shares of Prothena from a “sell” rating to a “hold” rating in a research note on Thursday, December 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a research note on Friday, November 23rd. Finally, Zacks Investment Research raised shares of Prothena from a “hold” rating to a “strong-buy” rating and set a $13.00 price objective for the company in a research report on Tuesday.

Shares of NASDAQ:PRTA traded up $0.38 during midday trading on Friday, reaching $11.63. 24,057 shares of the company were exchanged, compared to its average volume of 465,975. Prothena has a fifty-two week low of $8.63 and a fifty-two week high of $46.14. The firm has a market cap of $450.86 million, a price-to-earnings ratio of -2.84 and a beta of 2.43.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.43. Prothena had a negative net margin of 18,276.97% and a negative return on equity of 43.17%. The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.26 million. Equities analysts predict that Prothena will post -3.87 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in PRTA. Oppenheimer & Co. Inc. grew its position in shares of Prothena by 47.7% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 11,455 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 3,700 shares during the period. Raymond James & Associates bought a new stake in shares of Prothena during the 2nd quarter worth about $170,000. Marshall Wace LLP bought a new stake in shares of Prothena during the 3rd quarter worth about $191,000. Trexquant Investment LP bought a new stake in shares of Prothena during the 3rd quarter worth about $301,000. Finally, Traynor Capital Management Inc. boosted its holdings in shares of Prothena by 21.1% during the 3rd quarter. Traynor Capital Management Inc. now owns 24,350 shares of the biotechnology company’s stock worth $318,000 after buying an additional 4,250 shares during the period.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.

Featured Article: 52-Week High/Low Prices For Stock Selection

Analyst Recommendations for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply